Hansa Biopharma AB (CHIX:HNSAS) NonCurrent Deferred Liabilities: kr0.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:HNSAS Hansa Biopharma AB CHIX:HNSAS
49 GF Score
Price kr25.64
GF Value kr19.38
! 6 Warning Signs
View Full Analysis

What is Hansa Biopharma AB NonCurrent Deferred Liabilities?

Hansa Biopharma AB CHIX:HNSAS 49 NonCurrent Deferred Liabilities is kr0.0 Mil as of Mar. 2026. GuruFocus rates CHIX:HNSAS with a GF Score™ of 49/100 and a GF Value™ of kr19.38. The stock has 6 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Hansa Biopharma AB's non-current deferred liabilities for the quarter that ended in Mar. 2026 was kr0.0 Mil.

Hansa Biopharma AB NonCurrent Deferred Liabilities Related Terms

Hansa Biopharma AB NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Hansa Biopharma AB's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hansa Biopharma AB NonCurrent Deferred Liabilities Chart

Hansa Biopharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Hansa Biopharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CHIX:HNSAS
49GF Score
Hansa Biopharma AB CHIX:HNSAS
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of kr0.0 Mil mean?
Hansa Biopharma AB (CHIX:HNSAS) has a NonCurrent Deferred Liabilities of kr0.0 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Hansa Biopharma AB and its competitors.
Is Hansa Biopharma AB's NonCurrent Deferred Liabilities too high?
Hansa Biopharma AB's current NonCurrent Deferred Liabilities is kr0.0 Mil. Overall, Hansa Biopharma AB has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Hansa Biopharma AB's NonCurrent Deferred Liabilities compare to VRTX and REGN?
Hansa Biopharma AB's NonCurrent Deferred Liabilities of kr0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Hansa Biopharma AB and its competitors. Hansa Biopharma AB's current NonCurrent Deferred Liabilities is kr0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansa Biopharma AB stock overvalued right now?
Hansa Biopharma AB (CHIX:HNSAS) has a current NonCurrent Deferred Liabilities of kr0.0 Mil. The stock's GF Value™ is kr19.38, compared to a current price of kr25.64 — trading 32.3% above its estimated fair value. The current NonCurrent Deferred Liabilities is kr0.0 Mil. Hansa Biopharma AB's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Hansa Biopharma AB (CHIX:HNSAS), the current NonCurrent Deferred Liabilities is kr0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hansa Biopharma AB (CHIX:HNSAS) Overvalued in 2026?

Based on GuruFocus' analysis, Hansa Biopharma AB stock appears to be overvalued. The current stock price of kr25.64 is trading 32.3% above its estimated GF Value™ of kr19.38.

Key valuation signals for CHIX:HNSAS:

  • NonCurrent Deferred Liabilities: kr0.0 Mil
  • GF Value™: kr19.38 vs. price of kr25.64 (32.3% above fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the CHIX:HNSAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hansa Biopharma AB Business Description

Address Scheelevagen 22, Lund, SWE, 223 63
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
49GF Score

Get the complete analysis for CHIX:HNSAS

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr25.64
Price
kr19.38
GF Value